Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

NCT06619561 is registered in ClinicalTrials.gov with Deciphera Pharmaceuticals, LLC as lead sponsor.

NCT NCT06619561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06619561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
Lead sponsor
Deciphera Pharmaceuticals, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
November 21, 2024
Completion date
October 31, 2029
Enrollment
48 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft-versus-host disease (cgvhd)